Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | APEX1 | P27695 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.67 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.67 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.67 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | PRKCI | P41743 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15383500 | 0.91 | PRKCI (0.56) | POLBALDH1A1MAPTHTTTDP1 | |
| SCHEMBL15383502 | 0.89 | AMY1A (0.61) | POLBALDH1A1MAPTHTTTDP1 | |
| SCHEMBL20175929 | 0.88 | PRKCI (0.53) | POLBALDH1A1MAPTHTTTDP1 | |
| SCHEMBL23080065 | 0.83 | TAAR1 (0.50) | POLBALDH1A1MAPTHTTTDP1 | |
| SCHEMBL11131965 | 0.82 | POLB (0.69) | POLBALDH1A1MAPTHTTTDP1 | |
| SCHEMBL13799707 | 0.81 | PRKCI (0.62) | POLBALDH1A1MAPTHTTTDP1 | |
| SCHEMBL15999194 | 0.80 | JAK2 (0.85) | POLBALDH1A1MAPTHTTTDP1 | |
| Bromide SCHEMBL11132004 | 0.80 | POLB (0.67) | POLBALDH1A1MAPTHTTTDP1 | |
| SCHEMBL11269728 | 0.80 | POLB (0.67) | POLBALDH1A1MAPTHTTTDP1 | |
| SCHEMBL11622498 | 0.80 | PRKCI (0.52) | POLBALDH1A1MAPTHTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005087901-A2 | FUEL ADDITIVE COMPOSITION HAVING ANTIKNOCK PROPERTIES | INNOSPEC LIMITED (GB) | 2005-09-22 | — | — | WO | claimed |
| US-9868975-B2 | Use of known compounds as D-amino acid oxidase inhibitors | Tseng, Yufeng Jane (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170037448-A1 | USE OF KNOWN COMPOUNDS AS D-AMINO ACID OXIDASE INHIBITORS | TSENG, YUFENG JANE | 2017-02-09 | — | — | US | disclosed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| WO-2005087901-A2 | FUEL ADDITIVE COMPOSITION HAVING ANTIKNOCK PROPERTIES | INNOSPEC LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | KCNT1, KCNMA1, KCNJ2 | POLB 3986/4885ALDH1A1 2383/4885MAPT 158/4885 |
| US-20170037448-A1 | USE OF KNOWN COMPOUNDS AS D-AMINO ACID OXIDASE INHIBITORS | DAO, DDO, DDC | POLB 1285/4885ALDH1A1 182/4885MAPT 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.